Literature DB >> 16696648

Towards a vaccine for Cryptococcus neoformans: principles and caveats.

Kausik Datta1, Liise-anne Pirofski.   

Abstract

In the Damage-response framework of microbial pathogenesis, infectious diseases are one outcome of a host-microorganism interaction in a susceptible host. In cryptococcal disease, damage to the host is caused by Cryptococcus neoformans virulence determinants, the nature of the host response, or both. Further, the disease may be acute or reactivated from a latent state. Hence, a vaccine for C. neoformans would need to prevent disease resulting from either acute or reactivated infection. The evidence to support the development of a vaccine for C. neoformans that induces antibody-mediated immunity is discussed herein.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16696648     DOI: 10.1111/j.1567-1364.2006.00073.x

Source DB:  PubMed          Journal:  FEMS Yeast Res        ISSN: 1567-1356            Impact factor:   2.796


  28 in total

Review 1.  An insight into the antifungal pipeline: selected new molecules and beyond.

Authors:  Luis Ostrosky-Zeichner; Arturo Casadevall; John N Galgiani; Frank C Odds; John H Rex
Journal:  Nat Rev Drug Discov       Date:  2010-08-20       Impact factor: 84.694

2.  Antibody immunity and natural resistance to cryptococcosis.

Authors:  N Trevijano-Contador; L Pirofski
Journal:  Curr Trop Med Rep       Date:  2019-04-04

3.  Of mice and men, revisited: new insights into an ancient molecule from studies of complement activation by Cryptococcus neoformans.

Authors:  Liise-Anne Pirofski
Journal:  Infect Immun       Date:  2006-06       Impact factor: 3.441

4.  Vaccines to prevent systemic mycoses: holy grails meet translational realities.

Authors:  John N Galgiani
Journal:  J Infect Dis       Date:  2008-04-01       Impact factor: 5.226

5.  Antibody response to Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan in patients after solid-organ transplantation.

Authors:  Ziba Jalali; Lucky Ng; Nina Singh; Liise-anne Pirofski
Journal:  Clin Vaccine Immunol       Date:  2006-07

6.  Self-aggregation of Cryptococcus neoformans capsular glucuronoxylomannan is dependent on divalent cations.

Authors:  Leonardo Nimrichter; Susana Frases; Leonardo P Cinelli; Nathan B Viana; Antonio Nakouzi; Luiz R Travassos; Arturo Casadevall; Marcio L Rodrigues
Journal:  Eukaryot Cell       Date:  2007-06-15

7.  Cryptococcus neoformans capsular polysaccharide and exopolysaccharide fractions manifest physical, chemical, and antigenic differences.

Authors:  Susana Frases; Leonardo Nimrichter; Nathan B Viana; Antonio Nakouzi; Arturo Casadevall
Journal:  Eukaryot Cell       Date:  2007-12-21

8.  Cryptococcus neoformans enters the endolysosomal pathway of dendritic cells and is killed by lysosomal components.

Authors:  Karen L Wozniak; Stuart M Levitz
Journal:  Infect Immun       Date:  2008-08-04       Impact factor: 3.441

Review 9.  HIV and co-infections.

Authors:  Christina C Chang; Megan Crane; Jingling Zhou; Michael Mina; Jeffrey J Post; Barbara A Cameron; Andrew R Lloyd; Anthony Jaworowski; Martyn A French; Sharon R Lewin
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

10.  Extracellular vesicles produced by Cryptococcus neoformans contain protein components associated with virulence.

Authors:  Marcio L Rodrigues; Ernesto S Nakayasu; Debora L Oliveira; Leonardo Nimrichter; Joshua D Nosanchuk; Igor C Almeida; Arturo Casadevall
Journal:  Eukaryot Cell       Date:  2007-11-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.